.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF06_Abacavir.Abacavir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF06_Abacavir.Abacavir| name: | Abacavir |
| ATC code: | J05AF06 | route: | oral |
| n-compartments | 1 |
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) used as part of antiretroviral therapy (ART) for the treatment of HIV-1 infection in adults and children. It is approved for use in combination with other antiretroviral agents.
Pharmacokinetic parameters reported for healthy adult subjects after oral administration.
Zhao, W, et al., & Jacqz-Aigrain, E (2013). Population pharmacokinetics of abacavir in infants, toddlers and children. British journal of clinical pharmacology 75(6) 1525–1535. DOI:10.1111/bcp.12024 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23126277
Zhao, W, et al., & Jacqz-Aigrain, E (2012). Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. British journal of clinical pharmacology 73(4) 641–650. DOI:10.1111/j.1365-2125.2011.04121.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21988586
Singh, RP, et al., & Wynne, B (2021). Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. Clinical pharmacology in drug development 10(9) 985–993. DOI:10.1002/cpdd.996 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34265164